Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Operating Expenses: 2019-2024

Historic Operating Expenses for Foghorn Therapeutics (FHTX) over the last 6 years, with Dec 2024 value amounting to $125.3 million.

  • Foghorn Therapeutics' Operating Expenses fell 15.81% to $26.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $111.0 million, marking a year-over-year decrease of 14.36%. This contributed to the annual value of $125.3 million for FY2024, which is 11.81% down from last year.
  • According to the latest figures from FY2024, Foghorn Therapeutics' Operating Expenses is $125.3 million, which was down 11.81% from $142.1 million recorded in FY2023.
  • In the past 5 years, Foghorn Therapeutics' Operating Expenses registered a high of $142.1 million during FY2023, and its lowest value of $69.0 million during FY2020.
  • In the last 3 years, Foghorn Therapeutics' Operating Expenses had a median value of $136.4 million in 2022 and averaged $134.6 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first skyrocketed by 47.99% in 2021, then declined by 11.81% in 2024.
  • Foghorn Therapeutics' Operating Expenses (Yearly) stood at $69.0 million in 2020, then soared by 47.99% to $102.1 million in 2021, then skyrocketed by 33.62% to $136.4 million in 2022, then rose by 4.18% to $142.1 million in 2023, then fell by 11.81% to $125.3 million in 2024.